Arlene Naranjo
University of Florida
H-index: 45
North America-United States
Top articles of Arlene Naranjo
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Impact of Diagnostic and End-Induction Curie Scores with Tandem Autologous Transplants for Metastatic High-Risk Neuroblastoma: A Report from the Children’s Oncology Group | Authorea Preprints | Keri Streby Meg Parisi Barry Shulkin Brian LaBarre Rochelle Bagatell | 2023/1/13 |
A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study. | Tara O Henderson Jenna K Bardwell Pei-Chi Kao Paul C Nathan Wendy Landier | 2023/6/1 | |
Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma | Cell reports | Miriam I Rosenberg Erez Greenstein Martin Buchkovich Ayelet Peres Eric Santoni-Rugiu | 2023/8/29 |
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high‐risk neuroblastoma clinical trial | Pediatric Blood & Cancer | Olivia Campagne Huiyun Wu Jianrong Wu Arlene Naranjo Vinay M Daryani | 2023/11 |
Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the … | Pediatric Blood & Cancer | Keri A Streby Marguerite T Parisi Barry L Shulkin Brian LaBarre Rochelle Bagatell | 2023/8 |
Impact of genomic and clinical factors on outcome of children≥ 18 months of age with stage 3 neuroblastoma with unfavorable histology and without MYCN amplification: a … | Clinical Cancer Research | Navin Pinto Arlene Naranjo Xiangming Ding Fan F Zhang Emily Hibbitts | 2023/4/14 |
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12-to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification | Journal of Clinical Oncology | Hannah G Bender Meredith S Irwin Michael D Hogarty Robert Castleberry John M Maris | 2023/6/10 |
ANBL1531: The Children's Oncology Group (COG) Experience Using a Bayesian Approach | Arlene Naranjo Rochelle Bagatell Emily G Greengard Steven G DuBois | 2023/1/1 | |
Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial. | Emily Jones Arlene Naranjo Lena E Winestone Puja J Umaretiya Rahela Aziz-Bose | 2023/6/1 | |
Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions | Statistics in Biopharmaceutical Research | Rajeshwari Sridhara Olga Marchenko Qi Jiang Elizabeth Barksdale Todd A Alonzo | 2023/10/2 |
Persistence of racial and ethnic disparities in risk and survival for patients with neuroblastoma over two decades | EJC paediatric oncology | Mohansrinivas Chennakesavalu Caileigh Pudela Mark A Applebaum Sang Mee Lee Yan Che | 2023/12/1 |
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group | Journal for immunotherapy of cancer | Amy K Erbe Mitch B Diccianni Rajen Mody Arlene Naranjo Fan F Zhang | 2023 |
Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma … | Pediatric Blood & Cancer | Kevin Campbell Pei‐Chi Kao Arlene Naranjo Takehiko Kamijo Ramya Ramanujachar | 2023/2 |
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma | Pediatric Blood & Cancer | Philip J Lupo Erin L Marcotte Michael E Scheurer Jenny N Poynter Logan G Spector | 2023/9 |
Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk … | Wendy B London Hannah Bender Meredith Irwin Michael D Hogarty Robert P Castleberry | 2022/6/1 | |
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group | Pediatric blood & cancer | Prerna Kumar Victoria W Willard Leanne Embry Arlene Naranjo Brian Labarre | 2022/11/1 |
A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group. | Sara Michele Federico Arlene Naranjo Fan Zhang Araz Marachelian Ami Vijay Desai | 2022/6/1 | |
Expression of neuroblastoma‐related genes in bone marrow at end of high‐risk neuroblastoma therapy | Pediatric blood & cancer | Shahab Asgharzadeh Araz Marachelian Judith G Villablanca Wei Yao Liu Rebekah Kennedy | 2022/9 |
Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma. | Scott Moerdler Arlene Naranjo Sheena Tenney Rochelle Bagatell Alice L Yu | 2022/6/1 | |
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project | Pediatric blood & cancer | Kieuhoa T Vo Steven G DuBois John Neuhaus Steve E Braunstein Brent R Weil | 2022/9 |
Co-Authors
